ACTU

NASDAQ 已收盘

Actuate Therapeutics

0.23 USD
▲+0.01+5.38%
盘后 0.20 -11.05%
2026-11-20
市值
$12.39M
市盈率
—
EPS
-0.78
股息率
—
52 周区间
0.17 – 7.90
成交量
646.64K
Beta
1.53
目标价
7.00
52W 低 0.1752W 高 7.90
价格走势

公司简介

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company’s lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apothe...